GlassScriptPhysician profile
Emma C Harrison
NPI 1902291685
$3,001.36
in general payments reported to CMS, 2019-2025
14 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $881 · 2022: $893 · 2023: $939 · 2024: $93.51 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $660.11 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $620.51 | 2021-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $491.28 | 2021-2022 | |
| Corium, LLC | $434.21 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $208.69 | 2021-2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $157.59 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $142.90 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.91 | 2022 | |
| Lundbeck LLC | $48.85 | 2023-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $47.88 | 2022 | |
| Sunovion Pharmaceuticals INC. | $45.83 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $43.47 | 2022-2024 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $30.59 | 2021 | |
| Indivior INC. | $17.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.